Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rezolute (Nasdaq: RZLT) announced management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026 in New York.

Rhea-AI Summary

Rezolute (Nasdaq: RZLT) announced management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026 in New York. Management will hold one-on-one investor meetings during the conference. Investors should contact their Guggenheim representative to schedule meetings.

Argus Feb 4 session

-7.62% close to close Open Argus

Details

News Market Reaction – RZLT

On Feb 4, the day this news came out, RZLT closed 7.62% below the previous close.

Data tracked by StockTitan Argus for the Feb 4 session.

Key Figures

Conference dates: February 11–12, 2026

Conference dates

February 11–12, 2026

Guggenheim Emerging Outlook: Biotech Summit 2026

Historical Context

5 past events · Latest: Jan 07

5 events

1. Jan 07

   Clinical trial update

   24h Move

   +23.0%

   Further sunRIZE data and EAP outcomes after missed endpoints.

2. Dec 11

   Phase 3 topline

   24h Move

   -87.2%

   sunRIZE Phase 3 failed primary and key secondary endpoints.

3. Nov 10

   Equity inducement grant

   24h Move

   -7.5%

   Inducement stock options granted to new employees.

4. Nov 06

   Earnings and update

   24h Move

   +2.7%

   Fiscal Q1 2026 results and confirmation of Phase 3 timelines.

5. Nov 05

   Investor event

   24h Move

   +5.1%

   Announcement of virtual investor event on ersodetug program.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

hyperinsulinism (HI), hypoglycemia

2 terms

hyperinsulinism (HI) medical

"focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI)"

Hyperinsulinism (HI) is a medical condition where the body produces too much insulin, the hormone that lowers blood sugar, causing dangerously low glucose levels. For investors, HI matters because it drives demand for diagnostics, treatments, and long‑term care solutions; like a thermostat stuck too low, it creates a predictable market need for therapies and monitoring devices that companies may supply. Clinical advances or approvals can materially affect the value of related healthcare firms.

hypoglycemia medical

"focused on treating hypoglycemia caused by all forms of hyperinsulinism"

Hypoglycemia is a condition where blood sugar falls too low to fuel the body and brain, causing symptoms like shakiness, confusion, sweating or fainting. Think of it as a car running low on gas: systems slow or fail until fuel is restored. Investors care because treatments, devices or drugs that cause or prevent hypoglycemia affect patient safety, regulatory approval, product labeling and market acceptance, which influence a company’s commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place February 11-12, 2026 in New York.

Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim representative.

About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.

Rezolute Contacts:

Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
cmckim@rezolutebio.com
336-608-9706

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Rezolute (RZLT) participate in the Guggenheim Emerging Outlook: Biotech Summit 2026?

Rezolute management will attend the summit on February 11-12, 2026. According to Rezolute, management will be in New York for the Guggenheim Emerging Outlook: Biotech Summit and will hold one-on-one investor meetings throughout the two-day event to engage with shareholders and analysts.

What opportunities will Rezolute (RZLT) provide investors at the February 2026 Guggenheim biotech summit?

Investors can request one-on-one meetings with Rezolute management during the conference. According to Rezolute, these meetings are arranged through Guggenheim representatives and offer direct access to management for questions on strategy, programs, and corporate updates.

How can investors schedule a meeting with Rezolute (RZLT) at the Guggenheim Emerging Outlook: Biotech Summit?

Investors should contact their Guggenheim representative to arrange meetings with Rezolute management. According to Rezolute, Guggenheim handles scheduling for the February 11-12, 2026 summit, so investor requests should be routed through their Guggenheim contact.

Where is the Guggenheim Emerging Outlook: Biotech Summit 2026 where Rezolute (RZLT) will appear?

The summit will take place in New York on February 11-12, 2026. According to Rezolute, management will attend the New York event and participate in scheduled one-on-one investor meetings organized by Guggenheim representatives.

Will Rezolute (RZLT) host a public presentation at the Guggenheim Emerging Outlook: Biotech Summit 2026?

Rezolute announced management will participate and hold one-on-one investor meetings, but did not specify a public presentation. According to Rezolute, engagement at the February 11-12, 2026 summit will focus on scheduled investor meetings arranged through Guggenheim.